Periplocymarin alleviates pathological cardiac hypertrophy via inhibiting the JAK2/STAT3 signalling pathway

Pathological cardiac hypertrophy is the most important risk factor for developing chronic heart failure. Therefore, the discovery of novel agents for treating pathological cardiac hypertrophy remains urgent. In the present study, we examined the therapeutic effect and mechanism of periplocymarin (PM...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Cai‐lian, Liang, Sui, Ye, Meng‐nan, Cai, Wan‐jun, Chen, Miao, Hou, Yun‐long, Guo, Jun, Dai, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077305/
https://www.ncbi.nlm.nih.gov/pubmed/35365949
http://dx.doi.org/10.1111/jcmm.17267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077305/
https://www.ncbi.nlm.nih.gov/pubmed/35365949
http://dx.doi.org/10.1111/jcmm.17267

Ejemplares similares